A Paradigm Shift in Cytometry:
At DeePath, we are developing novel technologies to detect signaling protein expression levels in clinically relevant cell subsets by massively multiplexed cytometry. The SCALPEL assay employs novel multi-tube flow cytometry panels and Eyelis-based data analysis/visualization algorithms to detect rare activated cell types in blood and other biologic specimens. In essence, we do the following:
A. Identify phenotypic characteristics in relevant cell types by analyzing cell signaling patterns and activation profile through SCALPEL-based high parameter cytometry.
B. Based on the interpretation of signaling patterns through cell-based protein biomarkers, better understand the specific nature of the pathologic condition.
C. Apply the results of the novel assay and analytics to better guide treatment.
Our goal is to convey our science and technology, and current applications for more precise cell-based diagnostics in oncology and immunologic disorders. In addition to our primary technological and scientific capabilities, we will provide key information about our industry position, IP portfolio, and areas of interest.